NCT05847569 2026-02-03Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple MyelomaMayo ClinicPhase 2 Recruiting62 enrolled
NCT03941860 2025-05-23Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM TrialNational Cancer Institute (NCI)Phase 3 Completed1 enrolled 1 chart